Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Oct-Dec;8(4):629-641.
doi: 10.4103/jnrp.jnrp_168_17.

A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016

Affiliations
Review

A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016

Anshu Gupta et al. J Neurosci Rural Pract. 2017 Oct-Dec.

Abstract

After 8 years, an update of central nervous system (CNS) tumors was published in 2016 after 2007. First time ever, molecular markers along with histology have been used in classification of any tumor. Major changes are seen in glioma and medulloblastoma groups. Few entities have been added such as diffuse midline glioma, H3 K27M-mutant, RELA fusion-positive ependymoma, embryonal tumor with multilayered rosettes, C19MC-altered, and hybrid nerve sheath tumors. Few variants and patterns that no longer have diagnostic and/or biological relevance and have been deleted such as glioblastoma cerebri, protoplasmic and fibrillary astrocytoma, and cellular ependymoma. Other changes include deletion of term "primitive neuroectodermal tumor," addition of criterion of brain invasion in atypical meningioma, separation of melanotic schwannoma from other schwannoma, and combination of solitary fibrous tumors and hemangiopericytoma as one entity. There is also expansion of entities in nerve sheath tumors and hematopoietic/lymphoid tumors of the CNS. In this review article, we tried to review CNS tumors 2016 classification update in a simplified manner; comparing the differences between 2016 and 2007 CNS tumors classifications with brief description of important molecular markers and finally utility as well as challenges of this classification.

Keywords: Central nervous system tumor update; World Health Organization classification; simplified overview.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Similar articles

Cited by

References

    1. Louis DN. WHO classification and grading of tumours of central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Branger FD, et al., editors. WHO Classification of Tumours of the Central Nervous System. 4th ed., Revised. Lyon: International Agency for Research Centre; 2016. pp. 12–3.
    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131:803–20. - PubMed
    1. Louis DN. WHO classification of tumours of central nervous system. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Branger FD, et al., editors. WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon: International Agency for Research Centre; 2007. pp. 8–9.
    1. Grading of the Tumors of the Central Nervous System. [Last accessed on 2017 Mar 16]. Available from: https://www.en.wikipedia.org/wiki/Grading_of_the_tumors_of_the_central_n... .
    1. Louis DN, von Deimling A, Cavenee WK. Diffuse astrocytic and oligodendroglial tumours. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Branger FD, et al., editors. WHO Classification of Tumours of the Central Nervous System. 4th ed., Revised. Lyon: International Agency for Research Centre; 2016. pp. 15–56.